A citation-based method for searching scientific literature

Guochun Zhang, Chongyang Ren, Cheukfai Li, Yulei Wang, Bo Chen, Lingzhu Wen, Minghan Jia, Kai Li, Hsiaopei Mok, Li Cao, Xiaoqing Chen, Jiali Lin, Guangnan Wei, Yingzhi Li, Yuchen Zhang, Charles M Balch, Ning Liao. BMC Med 2022
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review.
Noam Pondé, Philippe Aftimos, Martine Piccart. Curr Treat Options Oncol 2019
29
100

HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis.
Ryan Shea Ying Cong Tan, Whee Sze Ong, Kyung-Hun Lee, Abner Herbert Lim, Seri Park, Yeon Hee Park, Ching-Hung Lin, Yen-Shen Lu, Makiko Ono, Takayuki Ueno,[...]. BMC Med 2022
1
100

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
D J Slamon, G M Clark, S G Wong, W J Levin, A Ullrich, W L McGuire. Science 1987
100

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, Freddie Bray. CA Cancer J Clin 2021
100

In Real Life, Low-Level HER2 Expression May Be Associated With Better Outcome in HER2-Negative Breast Cancer: A Study of the National Cancer Center, China.
Yiqun Li, Nilupai Abudureheiyimu, Hongnan Mo, Xiuwen Guan, Shaoyan Lin, Zijing Wang, Yimeng Chen, Shanshan Chen, Qiao Li, Ruigang Cai,[...]. Front Oncol 2022
1
100

Clinical significance of HER2-low expression in early breast cancer: a nationwide study from the Korean Breast Cancer Society.
Hye Sung Won, Juneyoung Ahn, Yongseon Kim, Jin Sung Kim, Jeong-Yoon Song, Hong-Kyu Kim, Jeeyeon Lee, Heung Kyu Park, Yong-Seok Kim. Breast Cancer Res 2022
3
100

Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.
Shanu Modi, Haeseong Park, Rashmi K Murthy, Hiroji Iwata, Kenji Tamura, Junji Tsurutani, Alvaro Moreno-Aspitia, Toshihiko Doi, Yasuaki Sagara, Charles Redfern,[...]. J Clin Oncol 2020
155
100

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.
Antonio C Wolff, M Elizabeth Hale Hammond, Kimberly H Allison, Brittany E Harvey, Pamela B Mangu, John M S Bartlett, Michael Bilous, Ian O Ellis, Patrick Fitzgibbons, Wedad Hanna,[...]. J Clin Oncol 2018
635
100

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
M Elizabeth H Hammond, Daniel F Hayes, Mitch Dowsett, D Craig Allred, Karen L Hagerty, Sunil Badve, Patrick L Fitzgibbons, Glenn Francis, Neil S Goldstein, Malcolm Hayes,[...]. J Clin Oncol 2010
100

Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond.
Caterina Marchiò, Laura Annaratone, Ana Marques, Laura Casorzo, Enrico Berrino, Anna Sapino. Semin Cancer Biol 2021
26
100

HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer.
Luciana de Moura Leite, Marcelle Goldner Cesca, Monique Celeste Tavares, Debora Maciel Santana, Erick Figueiredo Saldanha, Paula Tavares Guimarães, Daniella Dias Silva Sá, Maria Fernanda Evangelista Simões, Rafael Lima Viana, Francisca Giselle Rocha,[...]. Breast Cancer Res Treat 2021
7
100

Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial.
Arlene Chan, Beverly Moy, Janine Mansi, Bent Ejlertsen, Frankie Ann Holmes, Stephen Chia, Hiroji Iwata, Michael Gnant, Sibylle Loibl, Carlos H Barrios,[...]. Clin Breast Cancer 2021
52
100


HER2-Low Breast Cancer: Molecular Characteristics and Prognosis.
Elisa Agostinetto, Mattia Rediti, Danai Fimereli, Véronique Debien, Martine Piccart, Philippe Aftimos, Christos Sotiriou, Evandro de Azambuja. Cancers (Basel) 2021
20
100

HER2-Low Breast Cancer: Pathological and Clinical Landscape.
Paolo Tarantino, Erika Hamilton, Sara M Tolaney, Javier Cortes, Stefania Morganti, Emanuela Ferraro, Antonio Marra, Giulia Viale, Dario Trapani, Fatima Cardoso,[...]. J Clin Oncol 2020
70
100

Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials.
Carsten Denkert, Fenja Seither, Andreas Schneeweiss, Theresa Link, Jens-Uwe Blohmer, Marianne Just, Pauline Wimberger, Almuth Forberger, Hans Tesch, Christian Jackisch,[...]. Lancet Oncol 2021
29
100

Evolution of HER2-low expression from primary to recurrent breast cancer.
Federica Miglietta, Gaia Griguolo, Michele Bottosso, Tommaso Giarratano, Marcello Lo Mele, Matteo Fassan, Matilde Cacciatore, Elisa Genovesi, Debora De Bartolo, Grazia Vernaci,[...]. NPJ Breast Cancer 2021
7
100

HER2-positive advanced breast cancer treatment in 2020.
Marcelle G Cesca, Lucas Vian, Sofia Cristóvão-Ferreira, Noam Pondé, Evandro de Azambuja. Cancer Treat Rev 2020
30
100

Even low-level HER2 expression may be associated with worse outcome in node-positive breast cancer.
Michael Z Gilcrease, Wendy A Woodward, Marlo M Nicolas, Lynda J Corley, Gregory N Fuller, Francisco J Esteva, Susan L Tucker, Thomas A Buchholz. Am J Surg Pathol 2009
48
100

The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status.
Nanae Horisawa, Yayoi Adachi, Daiki Takatsuka, Kazuki Nozawa, Yuka Endo, Yuri Ozaki, Kayoko Sugino, Ayumi Kataoka, Haruru Kotani, Akiyo Yoshimura,[...]. Breast Cancer 2022
7
100

HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade.
Aleix Prat, Tomás Pascual, Carmine De Angelis, Carolina Gutierrez, Antonio Llombart-Cussac, Tao Wang, Javier Cortés, Brent Rexer, Laia Paré, Andres Forero,[...]. J Natl Cancer Inst 2020
56
100

Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry.
Simon Peter Gampenrieder, Gabriel Rinnerthaler, Christoph Tinchon, Andreas Petzer, Marija Balic, Sonja Heibl, Clemens Schmitt, August Felix Zabernigg, Daniel Egle, Margit Sandholzer,[...]. Breast Cancer Res 2021
3
100

Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer.
Raz Mutai, Tamar Barkan, Assaf Moore, Michal Sarfaty, Tzippy Shochat, Rinat Yerushalmi, Salomon M Stemmer, Hadar Goldvaser. Breast 2021
11
100

Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes.
Christine Desmedt, Benjamin Haibe-Kains, Pratyaksha Wirapati, Marc Buyse, Denis Larsimont, Gianluca Bontempi, Mauro Delorenzi, Martine Piccart, Christos Sotiriou. Clin Cancer Res 2008
580
100

Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.
Udai Banerji, Carla M L van Herpen, Cristina Saura, Fiona Thistlethwaite, Simon Lord, Victor Moreno, Iain R Macpherson, Valentina Boni, Christian Rolfo, Elisabeth G E de Vries,[...]. Lancet Oncol 2019
125
100

Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status.
Alexander Hein, Andreas D Hartkopf, Julius Emons, Michael P Lux, Bernhard Volz, Florin-Andrei Taran, Friedrich Overkamp, Peyman Hadji, Hans Tesch, Lothar Häberle,[...]. Eur J Cancer 2021
5
100

Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer.
Holm Eggemann, Tanja Ignatov, Elke Burger, Eva Johanna Kantelhardt, Franziska Fettke, Christoph Thomssen, Serban Dan Costa, Atanas Ignatov. Endocr Relat Cancer 2015
38
100

Moderate level of HER2 expression and its prognostic significance in breast cancer with intermediate grade.
Tanja Ignatov, Holm Eggemann, Elke Burger, Franziska Fettke, Serban Dan Costa, Atanas Ignatov. Breast Cancer Res Treat 2015
11
100

New strategies in estrogen receptor-positive breast cancer.
Stephen R D Johnston. Clin Cancer Res 2010
154
100

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer.
Francesco Schettini, Nuria Chic, Fara Brasó-Maristany, Laia Paré, Tomás Pascual, Benedetta Conte, Olga Martínez-Sáez, Barbara Adamo, Maria Vidal, Esther Barnadas,[...]. NPJ Breast Cancer 2021
51
100

Molecular portraits of human breast tumours.
C M Perou, T Sørlie, M B Eisen, M van de Rijn, S S Jeffrey, C A Rees, J R Pollack, D T Ross, H Johnsen, L A Akslen,[...]. Nature 2000
100

Evolution of low HER2 expression between early and advanced-stage breast cancer.
Paolo Tarantino, Sara Gandini, Eleonora Nicolò, Pamela Trillo, Federica Giugliano, Paola Zagami, Grazia Vivanet, Federica Bellerba, Dario Trapani, Antonio Marra,[...]. Eur J Cancer 2022
1
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.